Investing - Small-Cap Market Intelligence

Investing - Small-Cap Market Intelligence

Micro and small cap, investor relations, and financial news.

Investing - Small-Cap Market Intelligence
  • DSS: Rapid Growth Across Diverse Business Segments

    Interview with COO of Document Security Systems (NYSE American: DSS). DSS is a multinational company operating businesses focused on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets. Its business model is based on a distri...

  • Lantern Pharma: AI-Based Drug Discovery and Development Targeting Cancer

    Lantern Pharma (NASDAQ: LTRN) is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to transform the cost, risk and timeline of oncology drug discovery and development. Lantern utilizes its proprietary RADR® A.I. platfo...

  • Tiziana: Transforming Treatments for Multiple Diseases

    Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS) is developing targeted therapeutics to transform treatment of liver diseases, inflammatory diseases, and cancer. Our clinical pipeline includes drug assets for Crohn's, and hepatocellular carcinoma. Tiziana’s two lead drug candidates, Foralumab and ...

  • Exclusive interview with Aptorum Group (NASDAQ: APM) President Darren Lui

    Exclusive interview with Aptorum Group (NASDAQ: APM) President Darren Lui. Aptorum is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum's current drug pipeline includes indications in orphan diseases, infectious diseases...

  • OKYO Pharma Developing Novel Treatments for Eye Diseases

    OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain

  • Lantern Pharma (NASDAQ: LTRN) AI-Based Drug Discovery Targeting Cancer

    Lantern Pharma (NASDAQ: LTRN) is a clinical stage biotechnology company focused on innovating the cancer drug development process by rescuing and repositioning drug candidates that others have tried, but failed, to develop and developing new drugs of its own using advanced genomics and artificial...

  • COMSovereign Holding (OTC: COMS) U.S.-Based Pure-Play Communications Solutions

    COMSovereign Holding (OTC: COMS) has assembled a portfolio of US-based communications technology companies whose combined capabilities enable connectivity across the entire data transmission spectrum. Through strategic acquisitions and organic research and development efforts, COMSovereign is see...

  • Interview with CEO Better Choice: Rapidly Growing Pet Food Company

    Better Choice Company (OTCQB: BTTR) is a rapidly growing animal health and wellness company committed to leading the industry shift toward pet products and services that help dogs and cats live healthier, happier, and longer lives. Better Choice generated nearly $50 million in revenue in 2019 on ...

  • New FinTech Targeting Unmet Needs of Underbanked Consumers in US

    Cuentas (OTCQB: CUEN) provides innovative mobile banking, mobility, and telecommunications solutions to underserved, unbanked, and emerging markets. The Company’s portfolio of fintech solutions meet the highest-volume services demand of the estimated 70 million underbanked and unbanked consumers ...

  • Aptorum (NASDAQ: APM) Multi-Pillar Drug Development with Near-Term Revenue

    Aptorum Group (NASDAQ: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum's current drug pipeline includes indications in orphan diseases, infectious diseases, and metabolic diseases. In 2020 the company plans to ...

  • Annovis Bio A Potential Game Changer in Alzheimer’s Treatment

    Exclusive interview with Dr. Maria Maccecchini, Founder and CEO of Annovis Bio (NYSE American: ANVS), a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to b...

  • BioLargo CEO Interview: Record Revenues, New Partnerships, and more

    Exclusive interview with BioLargo (OTCQB: BLGO) CEO Dennis Calvert. BioLargo is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”. The Company feature unique disruptive solutions to deliver clean air, clean water ...

  • Milestone Scientific CEO Interview: Game-Changing Injection Technology

    Watch our exclusive interview with Milestone Scientific (NYSE American: MLSS) CEO Leonard Osser. Milestone Scientific is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and ins...

  • CIIX High Growth Investment Opportunity Targeting Chinese Speaking Communities

    ChineseInvestors.com (OTCQB: CIIX) has built a large base of Chinese-speaking consumers over its 20-year history. Since its founding in 1999, the company focused on providing financial news and information through its proprietary platform ChineseInvestors.com, which continues to generate subscrip...

  • Can-Fite BioPharma Ltd. (NYSE American: CANF)

    Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical-stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases includi...

  • Ethema Health: New Paradigm in Mental Health Treatment

    Ethema Health Corporation (OTCQB: GRST) operates in the behavioral healthcare space, specifically in the treatment of substance-use disorders. The company has developed a unique treatment model that has shown to be highly effective at treating opioid addiction. Launched in 2011, Ethema plans to o...

  • Cyclo Therapeutics (CTDH)

    Cyclo Therapeutics (CTDH) is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C (NPC), a rare...

  • Developing Innovative Treatments for Alzheimer's

    Cyclo Therapeutics (CTDH) is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C (NPC), a rare...

  • Interview with iSIGN CEO Philip Sassower

    iSIGN (OTC: ISGN) is a leading provider of digital transaction management (DTM) software enabling fully digital (paperless) business processes. iSIGN’s solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and variou...

  • CTD Holdings (OTCQB: CTDH)

    CTD Holdings (OTCQB: CTDH) is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C (NPC), a rar...

  • SG Blocks (NASDAQ: SGBX)

    Watch our exclusive interview with SG Blocks (NASDAQ: SGBX), a premier innovator in advancing and promoting the use of code-engineered cargo shipping containers for safe and sustainable construction. SGBX offers a product that exceeds many standard building code requirements, and also supports de...

  • Elixinol (OTCQX: ELLXF)

    Watch our exclusive interview with Elixinol (OTCQX: ELLXF) co-founder Paul Benhaim. Elixinol is widely regarded as one of the most influential CBD brands in the world. With a proven track record of growing and extracting premium-quality hemp, Elixinol is one of the few CBD hemp extract brands wit...

  • cbdMD (NYSE American: YCBD)

    Exclusive Interview with cbdMD (NYSE American: YCBD) CEO Marty Sumichrast discussing the company's rapid growth in a multi-billion-dollar market. The relative newcomer to its industry surpassed a $20M annual revenue run rate in its second quarter of fiscal year 2019 (ended March) and is well-posi...

  • Wuhan General (OTC: WUHN)

    Watch our exclusive interview with the CEOs of MJ MedTech, a subsidiary of Wuhan General (OTC: WUHN), and Biodelta, as they discuss the company's near-term rollout in South Africa and plans to expand into neighboring countries. An early entrant in a multi-billion-dollar market opportunity, WUHN i...